Illumina Introduces Illumina SeqLab
July 16 2015 - 6:30AM
Business Wire
Enables Customers to Quickly Scale to
Population-size Production Capacity on HiSeq X Systems
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of
Illumina SeqLab, an integrated solution for customers with HiSeq X™
Systems to enable large-scale human whole-genome sequencing
operations. Designed to increase laboratory efficiency for
population-scale, human whole-genome sequencing (HWGS), this new
offering provides a complete solution for Illumina customers who
need streamlined workflows with integrated sample tracking and fast
and accurate analysis solutions. Illumina partnered with GenoLogics
and Hamilton Robotics to provide this streamlined end-to-end
solution which includes Clarity LIMS X Edition, Microlab® STAR™
liquid handling robotics, HiSeq® Analysis Software (HAS) v2.0 and
Illumina SeqLab Consulting Service.
“This complete solution was important in our decision to
purchase the HiSeq X System and to undertake population-scale
whole-genome sequencing of large well-characterized cohorts in
Scotland,” said Professor David Hume, Director of The Roslin
Institute at the University of Edinburgh, which provided funding
along with the Biotechnology and Biological Sciences Research
Council for the HiSeq X System to be installed in the
Institute.
Professor Tim Aitman, Director of Clinical Genomics in Edinburgh
Genomics at the University of Edinburgh, added, “Having access to
the best-in-class tools and quick access to service gives us
confidence that we can ramp up quickly and spend more time studying
the genomes of cancer patients, children with rare diseases, and
people with disorders of the central nervous system, while spending
less time on setting up our sequencing center.”
For laboratories that are new to population-level sequencing,
developing and configuring the laboratory automation and software
capabilities needed to process thousands of genomes per year can
take significant resources and an extended period of time. The
Illumina SeqLab plug-and-play solution helps laboratories maximize
efficiency, optimize laboratory utilization and streamline analysis
to enable maximum sample throughput in as little as six weeks.
Moreover, it helps laboratories to deliver sequence results with
confidence by enabling positive sample tracking throughout the
laboratory process. As part of the service, expert consultants
provide customers with detailed recommendations as they deploy
Illumina’s suite of world-class technologies, leveraging the
company’s more than 15 years of experience with genomics.
“The interest we’ve seen in population-scale sequencing as a
result of the launch of the Illumina HiSeq X Ten Sequencing System
last year and subsequent launch of the Illumina HiSeq X Five
Sequencing System has far outpaced our expectations,” said Illumina
Senior Vice President of Life Sciences, Kirk Malloy. “With this new
solution, we are enabling more laboratories to undertake
large-scale sequencing programs by providing them with premium
solutions to scale rapidly and maximize efficiency.”
Illumina SeqLab for large-scale HWGS is now shipping. For more
information, visit www.illumina.com/illuminaseqlab.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements include challenges inherent in developing,
manufacturing, and launching new products and services and the
other factors that are detailed in our filings with the Securities
and Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150716005270/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Mina
Nicoletti858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024